RSS   Newsletter   Contact   Advertise with us
Post Online Media

Eli Lilly & Co. expands immuno-oncology collaboration with Merck

Pharma industry   FDA granted accelerated approval

Eli Lilly and Compan announced the expansion of an existing immuno-oncology collaboration with Merck.

They will add a new study of Lilly's Lartruvo (olaratumab) with Keytruda (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma (STS).

Notably, the U.S. Food and Drug Administration (FDA) recently granted accelerated approval for Lartruvo in combination with doxorubicin, for the treatment of adults with STS with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.

Lartruvo in combination with doxorubicin, also recently received conditional marketing authorization from the European Medicines Agency for the treatment of adults with advanced STS not amenable to curative treatment.


What to read next


POST Online Media does not use cookies to collect information about visitors.   OK, hide this message   Third party ads may be using cookies, you can see how here.